StockTake
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Bioxyne.
RELATED STOCKHEAD STORIES
Health & Biotech
Bioxyne to raise $3 million for European markets expansion
Health & Biotech
Psilocybin can tackle brain injuries and binge eating, and these ASX companies are in the game
Health & Biotech
ASX Quarterly Health Wrap: Bioxyne revenue up 77%, Radiopharm lists on Nasdaq
Health & Biotech
Could Trump’s second act boost these ASX psychedelic stocks?
Health & Biotech
Health Check: Chinese consumer market is a thing of beauty, says EZZ Life Sciences
Health & Biotech
Biocurious: From drug prices to efficiency drives, ASX biotechs await the ‘Trumpcare’ health fallout
News
Closing Bell: Cannabis stocks bounce back; Ovanti soars 275pc after hiring Zip’s ex-CFO
Health & Biotech
Bioxyne’s revenue soars 48pc after key manufacturing licences boost growth
Health & Biotech
Health Check: ‘Cannabis corner’ in the green with record revenues and favourable deals
News
Top 10 at 11: Investor action, board room change and solid quarterly growth are today’s news
Health & Biotech
Health Check: Experts deliver their verdict on the Healius imaging deal and it’s ‘yeah nah’
Long Shortz
Long Shortz with Bioxyne: Cannabis pastilles in an Aussie first
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: Windy day for stocks as ANZ, Tabcorp get stung by regulators
News
ASX Lunch Wrap: Jumbo, Inghams, Accent sink, ending ASX winning streak
News
ASX Lunch Wrap: Shares on track for 10th straight gain, First Lithium soars, Megaport sinks 20pc
Break It Down
